Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS

NCT03280056 is registered in ClinicalTrials.gov with Brainstorm-Cell Therapeutics as lead sponsor.

NCT NCT03280056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03280056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS
Lead sponsor
Brainstorm-Cell Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
August 28, 2017
Completion date
September 29, 2020
Enrollment
196 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)